Obesity has been declared a disease by WHO. It is associated not only with heart disease, diabetes, stroke, gallstones, ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Structure Therapeutics (GPCR) announced the first patients have been dosed in the randomized, double-blind, placebo-controlled Phase 2b ACCESS ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

The use of this peptide-based GLP-1/glucagon dual receptor agonist is currently being ... who runs the Biotech Analysis ...

A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...

The study highlights the need for randomized clinical trials to confirm the efficacy of GLP-1 agonists in treating AUD and ...

GLP-1 drugs have been linked to numerous potential health benefits like treatment of existing conditions including heart ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a study ...

So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

Garner, MD, Medical Director at SimpleFixRx to review it all for accuracy. Dr, Garner said, "Glucagon-like peptide-1 (GLP-1) ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...